Kalaris Therapeutics Inc (KLRS) — Financial statements
Income statement, balance sheet, and cash flow for Kalaris Therapeutics Inc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.01 | 0.00 | 0.00 | 0.00↓100.0% | 1 | |
| Gross Profit | -0.01 | 0.00 | 0.00 | 0.00↑100.0% | -1 | |
| Operating Expenses | ||||||
| R&D Expenses | 31↑149.2% | 12↑5.4% | 12↓0.5% | 12↓90.2% | 120 | |
| General & Administrative Expenses | 0.00 | 0.00↓100.0% | 2↓21.7% | 2 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 15↓64.1% | 43↑2342.6% | 2↓21.7% | 2↓95.4% | 49 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 46↓16.5% | 55↑310.4% | 13↓3.9% | 14↓91.7% | 169 | |
| Total Costs & Expenses | 46↓16.5% | 55↑310.4% | 13↓3.9% | 14↓91.8% | 170 | |
| Operating Results | ||||||
| Operating Income | -46↑16.5% | -55↓310.4% | -13↑3.9% | -14↑91.8% | -170 | |
| Depreciation & Amortization | 0.01 | 0.00 | 0.00 | 0.00↓100.0% | 1 | |
| EBITDA | -46↑21.5% | -59↓319.4% | -14↑8.1% | -15↑91.0% | -170 | |
| EBIT | -46↑21.5% | -59↓319.4% | -14↑8.1% | -15↑91.1% | -171 | |
| Interest & Other Income | ||||||
| Net Interest Income | -1↓126.3% | 5↑898.5% | -0.69↓192.3% | -0.24↓117.9% | 1 | |
| Interest Income | 0.00↓100.0% | 5 | 0.00 | 0.00↓100.0% | 1 | |
| Interest Expense | 1 | 0.00↓100.0% | 0.69↑192.3% | 0.24 | 0.00 | |
| Non-Operating Income | 0.00↓100.0% | 4↑541.1% | 0.55↓55.9% | 1↑9.4% | 1 | |
| Other Income / Expenses | 3↑177.3% | -4↓184.5% | -1↑16.5% | -1↓30.1% | -1 | |
| Income Before Tax | -43↑26.1% | -59↓299.8% | -15↑5.1% | -15↑90.9% | -171 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -43↑26.1% | -59↓299.8% | -15↑5.1% | -15↑91.0% | -172 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -43↑26.1% | -59↓299.8% | -15↑5.1% | -15↑91.0% | -172 | |
| Bottom-Line Net Income | -43↑26.1% | -59↓299.8% | -15↑5.1% | -15↑91.0% | -172 | |
| EPS (Basic) | -2.85↑75.7% | -11.73↑72.1% | -42.09↑16.9% | -50.62↑19.6% | -63.00 | |
| EPS (Diluted) | -2.85↑75.7% | -11.73↑72.1% | -42.09↑16.9% | -50.62↑19.6% | -63.00 | |
| Weighted Average Shares | 15↑204.8% | 5↑10.7% | 5↑35.7% | 3↑22.1% | 3 | |
| Weighted Average Diluted Shares | 15↑204.8% | 5↑10.7% | 5↑35.7% | 3↑22.1% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.